drugset / Trial / NCT04606394
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
Phase 4
Completed
30 enrolled
Pulmonary Research Institute of Southeast Michigan
GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine the testing capabilities of the preferred PIF maneuver and to relate this PIF measurement to meaningful clinical outcomes in COPD patients
Timeline
- Start
- 2020-12-02
- Primary completion
- 2021-12-15
- Completion
- 2021-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Salbutamol | Unknown | 90 ug | Inhaled |
| Subject | Trelegy Ellipta | Unknown | 25 ug | Inhaled |
| Subject | Trelegy Ellipta | Unknown | 62.5 ug | Inhaled |
| Subject | Trelegy Ellipta | Unknown | 100 ug | Inhaled |